AIM:To compare the short-term effectiveness of intelligent navigated laser photocoagulation and 577-nm subthreshold micropulse laser(SML)treatment in patients with chronic central serous chorioretinopathy(cCSC).METHOD...AIM:To compare the short-term effectiveness of intelligent navigated laser photocoagulation and 577-nm subthreshold micropulse laser(SML)treatment in patients with chronic central serous chorioretinopathy(cCSC).METHODS:This observational retrospective cohort study included 60 consecutive patients who underwent intelligent navigated laser photocoagulation(n=30)or 577-nm SML treatment(n=30)for cCSC between Jan.2021 and Oct.2022.During 3mo follow-up,all patients underwent assessments of best correct visual acuity(BCVA)and optical coherence tomography(OCT).RESULTS:The operation of laser treatment was successful in all cases.At 1mo,BCVA improved significantly more in the intelligent navigated laser photocoagulation group compared to the SML group(P<0.05).The change was not significantly different at 3mo(P>0.05).Central macular thickness(CMT)in the intelligent navigated laser photocoagulation group was lower than in the SML group at 1mo(P<0.05).The subfoveal choroidal thickness(SFCT)in two groups were all significantly improved at 3mo(all P<0.05).The change between two groups was not significantly different at 1mo or at 3mo(P>0.05).CONCLUSION:Intelligent navigated laser photocoagulation is superior to SML for treating cCSC,leading to better improvements in vision and CMT for short term.展开更多
AIM:To evaluate the efficacy and safety of subthreshold micropulse yellow laser(SMYL)in the treatment of chronic central serous chorioretinopathy(CCSC).METHODS:The medical records of 58 eyes of 58 patients with CCSC w...AIM:To evaluate the efficacy and safety of subthreshold micropulse yellow laser(SMYL)in the treatment of chronic central serous chorioretinopathy(CCSC).METHODS:The medical records of 58 eyes of 58 patients with CCSC were reviewed.A 577-nm SMYL system was used for the treatment.Fundus fluorescein angiography was used as the primary method of identifying CCSC,and resolution of subretinal fluid(SRF)evaluated by optical coherence tomography(OCT)and fundus autofluorescence.Central macular thickness(CMT),central macular volume(CMV),total macular volume(TMV),subfoveal choroidal thickness(SFCT),subretinal fluid height(SRFH),and subfoveal fluid basement diameter values were measured by spectral domain-OCT(SD-OCT)for all eyes.RESULTS:The mean age of the patients was 42.4±9.9(range:20-72)y.The mean follow-up was 11.4±8.5(range:6-37)mo.Median BCVA at at the final follow up after treatment was statistically significant from the baseline.Complete SRF resolution was 12.1%of the eyes in the 1^st month,67.2%of the eyes in the 3rd month and 67.2%of the eyes in the last follow up.The initial median CMT,CMV,TMV,and SFCT values before treatment was significantly higher than 3^rd month visit values(P<0.001).In the multivariate analysis performed,age and disease duration were found to be a risk factor for persistent SRF(P=0.017,P=0.016,respectively).CONCLUSION:SMYL treatment provides a significant anatomical and functional improvement and is effective in eliminating SRF in eyes with CCSC.展开更多
·AIM:To analyze the efficacy and safety of subthreshold micropulse laser(SML)in the treatment of acute central serous chorioretinopathy(CSC).·METHODS:This is a retrospective case analysis study.Totally 58 ey...·AIM:To analyze the efficacy and safety of subthreshold micropulse laser(SML)in the treatment of acute central serous chorioretinopathy(CSC).·METHODS:This is a retrospective case analysis study.Totally 58 eyes of 58 patients were enrolled,and they were divided into different groups.And 39 patients were treated with SML(SML group)and 19 patients were only observed(observation group).The follow-up period was 3mo after diagnosis.The best corrected visual acuity(BCVA),central retinal thickness(CRT),superficial retinal vascular density(SRVD),deep retinal vascular density(DRVD),the superficial and deep foveal avascular zone(FAZ)area,retinal light sensitivity(RLS),perfusion area of choroidal capillary layer(CCL),subfoveal choroidal thickness(SFCT)and fundus autofluorescence(FAF)were investigated.·RESULTS:The BCVA,CRT,SRVD,DRVD,the superficial and deep FAZ area,RLS,SFCT of SML group were significantly improved at 3mo(all P<0.05).In the observation group,only CRT,DRVD and SFCT were improved(all P<0.05).Other research items in the observation group were not significantly different from baseline(all P>0.05).At the last follow-up,the BCVA and RLS in the SML group were better than those in the observation group,and CRT was lower,SRVD and DRVD,perfusion area of CCL were larger(all P<0.05).On FAF,no change of treatment spots was found after treatment.No structural laser damage was observed on optical coherence tomography(OCT)and optical coherence tomography angiography(OCTA),and no choroidal neovascularization was observed.·CONCLUSION:SML treatment of acute CSC can improve BCVA,RLS,and perfusion area of CCL,reduce CRT,increase SRVD and DRVD,and is safe.展开更多
Purpose:Subthreshold micropulse laser(SML)and photodynamic therapy(PDT)are among the most effective therapeutic modalities applied to central serous chorioretinopathy(CSCR).This study aimed to evaluate the ef-ficacy a...Purpose:Subthreshold micropulse laser(SML)and photodynamic therapy(PDT)are among the most effective therapeutic modalities applied to central serous chorioretinopathy(CSCR).This study aimed to evaluate the ef-ficacy and durability of PDT in CSCR cases unresponsive to at least two SML treatments.Methods:The study included 26 consecutive eyes of 24 patients(21 males and three females)with chronic CSCR.In all cases,a lack of reduction in subretinal fluid(SRF)levels was noted after at least two consecutive SML sessions.The parameters of best corrected visual acuity(BCVA)and spectral domain optical coherence tomog-raphy(SD-OCT)were evaluated at baseline and 1,3 and 12 months post-PDT.Results:The mean duration of symptoms in the group was 53.81±39.48 months,the mean age of the patients was 49.26±12.91 years,and the mean subfoveal choroidal thickness(SFCT)was 572.11±116.21 mm.Complete resorption of SRF was observed in 21 out of 26 eyes(80.77%)at 1 month and sustained in 18 cases(69.23%)at 12 months.At 12 months,in the sustained group,BCVA improved significantly from 0.39±0.18 to 0.19±0.2 logMAR(P=0.01),central subfoveal thickness(CST)reduced from 316.44±75.83 mm to 197.67±22.99 mm(P<0.0001),and SFCT reduced from 579.28 mm to 446.78 mm(P<0.0001).Conclusions:PDT provides the opportunity for the successful treatment of CSCR unresponsive to SML treatment.Improvements are possible even in cases with a long duration of symptoms and significant alterations in retinal morphology.Thus,PDT should be considered for patients with prominently increased choroidal thickness.展开更多
Background and Objective:Subthreshold laser therapy has emerged as a therapeutic alternative to traditional laser photocoagulation for certain ophthalmic diseases including central serous chorioretinopathy(CSCR),diabe...Background and Objective:Subthreshold laser therapy has emerged as a therapeutic alternative to traditional laser photocoagulation for certain ophthalmic diseases including central serous chorioretinopathy(CSCR),diabetic macular edema(DME),macular edema secondary to branch retinal vein occlusion(BRVO),and age-related macular degeneration(AMD).The objective of this paper is to review and discuss the clinical applications of subthreshold laser and the mechanisms of different subthreshold laser techniques including subthreshold micropulse laser(SMPL),selective retina therapy(SRT),subthreshold nanosecond laser(SNL),endpoint management(EpM),and transpupillary thermotherapy(TTT).Methods:A narrative review of English literature and publicly available information published before November 2021 from literature databases and computerized texts.We discuss the currently available subthreshold laser systems and the advancements made to perform different subthreshold laser techniques for various ophthalmic diseases.We highlight various clinical studies and therapeutic techniques that have been conducted to further understand the effectiveness of subthreshold laser in the clinical setting.We conclude the article by covering emerging subthreshold laser systems that are currently being developed for future clinical use.The PubMed database was utilized for peer-reviewed articles and pertinent information on subthreshold systems was cited from publicly available online websites covering specific systems.Key Content and Findings:Various subthreshold laser systems have been developed to treat certain retinal diseases.Several systems are currently in development for future clinical applications.Conclusions:While conventional laser photocoagulation has been effective in treating various retinal diseases,subthreshold laser systems aim to provide a therapeutic effect without visible signs of damage to the underlying tissue.This technology may be particularly effective in treating macular disorders.Further clinical studies are needed to evaluate their role in the management of retinal diseases.展开更多
文摘AIM:To compare the short-term effectiveness of intelligent navigated laser photocoagulation and 577-nm subthreshold micropulse laser(SML)treatment in patients with chronic central serous chorioretinopathy(cCSC).METHODS:This observational retrospective cohort study included 60 consecutive patients who underwent intelligent navigated laser photocoagulation(n=30)or 577-nm SML treatment(n=30)for cCSC between Jan.2021 and Oct.2022.During 3mo follow-up,all patients underwent assessments of best correct visual acuity(BCVA)and optical coherence tomography(OCT).RESULTS:The operation of laser treatment was successful in all cases.At 1mo,BCVA improved significantly more in the intelligent navigated laser photocoagulation group compared to the SML group(P<0.05).The change was not significantly different at 3mo(P>0.05).Central macular thickness(CMT)in the intelligent navigated laser photocoagulation group was lower than in the SML group at 1mo(P<0.05).The subfoveal choroidal thickness(SFCT)in two groups were all significantly improved at 3mo(all P<0.05).The change between two groups was not significantly different at 1mo or at 3mo(P>0.05).CONCLUSION:Intelligent navigated laser photocoagulation is superior to SML for treating cCSC,leading to better improvements in vision and CMT for short term.
文摘AIM:To evaluate the efficacy and safety of subthreshold micropulse yellow laser(SMYL)in the treatment of chronic central serous chorioretinopathy(CCSC).METHODS:The medical records of 58 eyes of 58 patients with CCSC were reviewed.A 577-nm SMYL system was used for the treatment.Fundus fluorescein angiography was used as the primary method of identifying CCSC,and resolution of subretinal fluid(SRF)evaluated by optical coherence tomography(OCT)and fundus autofluorescence.Central macular thickness(CMT),central macular volume(CMV),total macular volume(TMV),subfoveal choroidal thickness(SFCT),subretinal fluid height(SRFH),and subfoveal fluid basement diameter values were measured by spectral domain-OCT(SD-OCT)for all eyes.RESULTS:The mean age of the patients was 42.4±9.9(range:20-72)y.The mean follow-up was 11.4±8.5(range:6-37)mo.Median BCVA at at the final follow up after treatment was statistically significant from the baseline.Complete SRF resolution was 12.1%of the eyes in the 1^st month,67.2%of the eyes in the 3rd month and 67.2%of the eyes in the last follow up.The initial median CMT,CMV,TMV,and SFCT values before treatment was significantly higher than 3^rd month visit values(P<0.001).In the multivariate analysis performed,age and disease duration were found to be a risk factor for persistent SRF(P=0.017,P=0.016,respectively).CONCLUSION:SMYL treatment provides a significant anatomical and functional improvement and is effective in eliminating SRF in eyes with CCSC.
文摘·AIM:To analyze the efficacy and safety of subthreshold micropulse laser(SML)in the treatment of acute central serous chorioretinopathy(CSC).·METHODS:This is a retrospective case analysis study.Totally 58 eyes of 58 patients were enrolled,and they were divided into different groups.And 39 patients were treated with SML(SML group)and 19 patients were only observed(observation group).The follow-up period was 3mo after diagnosis.The best corrected visual acuity(BCVA),central retinal thickness(CRT),superficial retinal vascular density(SRVD),deep retinal vascular density(DRVD),the superficial and deep foveal avascular zone(FAZ)area,retinal light sensitivity(RLS),perfusion area of choroidal capillary layer(CCL),subfoveal choroidal thickness(SFCT)and fundus autofluorescence(FAF)were investigated.·RESULTS:The BCVA,CRT,SRVD,DRVD,the superficial and deep FAZ area,RLS,SFCT of SML group were significantly improved at 3mo(all P<0.05).In the observation group,only CRT,DRVD and SFCT were improved(all P<0.05).Other research items in the observation group were not significantly different from baseline(all P>0.05).At the last follow-up,the BCVA and RLS in the SML group were better than those in the observation group,and CRT was lower,SRVD and DRVD,perfusion area of CCL were larger(all P<0.05).On FAF,no change of treatment spots was found after treatment.No structural laser damage was observed on optical coherence tomography(OCT)and optical coherence tomography angiography(OCTA),and no choroidal neovascularization was observed.·CONCLUSION:SML treatment of acute CSC can improve BCVA,RLS,and perfusion area of CCL,reduce CRT,increase SRVD and DRVD,and is safe.
基金approved by the local bioethics committee of Okrę-gowa Izba Lekarska w Gdansku(approval no.KB-35/23)on August 16,2023 and conducted according to the guidelines of the Declaration of Helsinki.
文摘Purpose:Subthreshold micropulse laser(SML)and photodynamic therapy(PDT)are among the most effective therapeutic modalities applied to central serous chorioretinopathy(CSCR).This study aimed to evaluate the ef-ficacy and durability of PDT in CSCR cases unresponsive to at least two SML treatments.Methods:The study included 26 consecutive eyes of 24 patients(21 males and three females)with chronic CSCR.In all cases,a lack of reduction in subretinal fluid(SRF)levels was noted after at least two consecutive SML sessions.The parameters of best corrected visual acuity(BCVA)and spectral domain optical coherence tomog-raphy(SD-OCT)were evaluated at baseline and 1,3 and 12 months post-PDT.Results:The mean duration of symptoms in the group was 53.81±39.48 months,the mean age of the patients was 49.26±12.91 years,and the mean subfoveal choroidal thickness(SFCT)was 572.11±116.21 mm.Complete resorption of SRF was observed in 21 out of 26 eyes(80.77%)at 1 month and sustained in 18 cases(69.23%)at 12 months.At 12 months,in the sustained group,BCVA improved significantly from 0.39±0.18 to 0.19±0.2 logMAR(P=0.01),central subfoveal thickness(CST)reduced from 316.44±75.83 mm to 197.67±22.99 mm(P<0.0001),and SFCT reduced from 579.28 mm to 446.78 mm(P<0.0001).Conclusions:PDT provides the opportunity for the successful treatment of CSCR unresponsive to SML treatment.Improvements are possible even in cases with a long duration of symptoms and significant alterations in retinal morphology.Thus,PDT should be considered for patients with prominently increased choroidal thickness.
文摘Background and Objective:Subthreshold laser therapy has emerged as a therapeutic alternative to traditional laser photocoagulation for certain ophthalmic diseases including central serous chorioretinopathy(CSCR),diabetic macular edema(DME),macular edema secondary to branch retinal vein occlusion(BRVO),and age-related macular degeneration(AMD).The objective of this paper is to review and discuss the clinical applications of subthreshold laser and the mechanisms of different subthreshold laser techniques including subthreshold micropulse laser(SMPL),selective retina therapy(SRT),subthreshold nanosecond laser(SNL),endpoint management(EpM),and transpupillary thermotherapy(TTT).Methods:A narrative review of English literature and publicly available information published before November 2021 from literature databases and computerized texts.We discuss the currently available subthreshold laser systems and the advancements made to perform different subthreshold laser techniques for various ophthalmic diseases.We highlight various clinical studies and therapeutic techniques that have been conducted to further understand the effectiveness of subthreshold laser in the clinical setting.We conclude the article by covering emerging subthreshold laser systems that are currently being developed for future clinical use.The PubMed database was utilized for peer-reviewed articles and pertinent information on subthreshold systems was cited from publicly available online websites covering specific systems.Key Content and Findings:Various subthreshold laser systems have been developed to treat certain retinal diseases.Several systems are currently in development for future clinical applications.Conclusions:While conventional laser photocoagulation has been effective in treating various retinal diseases,subthreshold laser systems aim to provide a therapeutic effect without visible signs of damage to the underlying tissue.This technology may be particularly effective in treating macular disorders.Further clinical studies are needed to evaluate their role in the management of retinal diseases.
